Short report: cefprozil for the eradication of Helicobacter pylori infection.
Author(s): Malaty H, Klein PD, Graham DY
Affiliation(s): Department of Medicine, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas.
Publication date & source: 1992-08, Aliment Pharmacol Ther., 6(4):503-6.
Publication type: Clinical Trial
Helicobacter pylori infection has proven to be extraordinarily difficult to eradicate. Antimicrobial monotherapies have been particularly disappointing, with most eradication rates in the range of 0 to 15%. We evaluated cefprozil (250 mg q.d.s. for 14 days) in 12 H. pylori-infected subjects. The 13C-urea breath test was used to evaluate effectiveness of therapy. Eradication was defined as a negative urea breath test 4 to 6 weeks after the end of treatment. Suppression of H. pylori was demonstrated in 4 of 12 (33%) by a negative urea breath test two days after start of treatment. H. pylori infection was not eradicated in any subject (0%). Adverse events were intermittent and mild. Cefprozil does not appear to offer promise as monotherapy for the eradication of H. pylori.
|